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The presence of two families of seven distinct mammalian cyclin-dependent kinase (CDK) inhibitor genes is
thought to mediate the complexity of connecting a variety of cellular processes to the cell cycle control pathway.
The distinct pattern of tissue expression of CDK inhibitor genes suggests that they may function as tumor
suppressors with different tissue specificities. To test this hypothesis, we have characterized two strains of
double mutant mice lacking either p18INK4c and p27KIP1 or p18INK4c and p21CIP1/WAF1. Loss of both p18 and
p27 function resulted in the spontaneous development by 3 months of age of at least eight different types of
hyperplastic tissues and/or tumors in the pituitary, adrenals, thyroid, parathyroid, testes, pancreas, duode-
num, and stomach. Six of these hyperplastic tissues and tumors were in endocrine organs, and several types
of tumors routinely developed within the same animal, a phenotype reminiscent of that seen in combined
human multiple endocrine neoplasia syndromes. The p18-p21 double null mice, on the other hand, developed
pituitary adenomas, multifocal gastric neuroendocrine hyperplasia, and lung bronchioalveolar tumors later in
life. G1 CDK2 and CDK4 kinase activities were increased in both normal and neoplastic tissues derived from
mice lacking individual CDK inhibitors and were synergistically stimulated by the simultaneous loss of two
CDK inhibitors. This indicates that an increase in G1 CDK kinase activity is a critical step during but is not
sufficient for tumor growth. Our results suggest that functional collaborations between distinct CDK inhibitor
genes are tissue specific and confer yet another level of regulation in cell growth control and tumor suppres-
sion.
More than a dozen tumor suppressor genes have been iden-
tified thus far by virtue of their genetic mutations in human
cancers. Some appear to function in a specific cell type, such as
BRCA1 and BRCA2 in breast and ovarian cancer, Smad4
(Dpc4), APC, and Smad2 in colon cancer, and Menin in type
1 multiple endocrine neoplasia (MEN1). Other tumor suppres-
sors, notably p53 and Rb, are mutated in a wide range of tumor
types, indicating a more general function in tumor suppression
(21, 32, 36). Conceptually, genes that negatively regulate the
growth-suppressing activity of either p53 or pRb may be proto-
oncogenes, as exemplified by the observation that MDM2 (26)
and cyclin D1 (20), negative regulators of p53 and pRb, re-
spectively, are frequently activated in human cancers and pro-
mote tumor growth when targeted for transgenic expression in
mouse mammary tissues (22, 35). Likewise, genes that function
to activate or to retain the growth suppression activity of either
p53 or pRb are candidate tumor suppressors (32, 33). Indeed,
the ARF-INK4a locus, the second most frequently disrupted
locus in human cancers next to p53 (17, 25), encodes two
separate proteins, ARF and p16INK4a, that positively regulate
p53 and Rb, respectively (33). The high frequency of genetic
alterations and the often nonoverlapping mutational pattern
among the genes within each of these two pathways have led to
the notion that functional inactivation of both the p53 and pRb
pathways may be necessary for the development of different
types of cancer.
Two families of cyclin-dependent kinase (CDK) inhibitors,
totaling seven genes, have been identified in mammalian cells.
Their similar biochemical activity in blocking CDK enzymes
and maintaining the growth-suppressive activity of Rb predict
a tumor suppression function for CDK inhibitor genes, yet only
the p16INK4a gene has been directly linked to tumor growth by
genetic alterations found in human cancers (17, 25) and by the
early development of spontaneous tumors in mice lacking p16
(31). Neither mutational analysis in human tumors nor pheno-
typic examination of genetically targeted mice lacking any of
the other individual CDK inhibitor genes has provided strong
evidence for a direct role for any of the other CDK inhibitors
as tumor suppressors. Mice lacking p21CIP1/WAF1 (6), p27KIP1
(10, 19, 23), p57KIP2 (40, 41), or p18INK4c (11) do not develop
spontaneous tumors at an early age. However, potential tumor
suppression functions were suggested by the observations that
cells lacking p21 are defective in a DNA damage-induced,
p53-mediated G1 checkpoint (3, 6), that mice lacking either
p18 or p27 slowly develop intermediate-lobe pituitary tumors
later in life (10, 11, 19, 23), that p27 heterozygous mice have a
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higher tumor incidence when challenged with g-irradiation (9),
and that Rb1/2-p272/2 mice developed more aggressive pitu-
itary adenoma and thyroid C-cell carcinomas than the Rb1/2
mice (27). The lack of more widely spread tumors in these
single-knockout mice may, in part, be due to a redundant or
overlapping function for many of these CDK inhibitors in
specific tissues. To test the possibility that different CDK in-
hibitor genes may functionally collaborate to suppress tumor
growth with different tissue specificities, we have characterized
the tumorigenesis of two strains of double mutant mice lacking
either p18 and p27 or p18 and p21.
MATERIALS AND METHODS
Creation of double null mice. Genetic disruptions of the p18 (11), p21 (6), and
p27 (19) loci have been previously described. Mice deficient for both p18 and p21
were created by mating p182/2 and p212/2 mice (6). The resulting F1 p181/2-
p211/2 mice were crossed to create the double null genotype. The creation of the
p182/2-p272/2 strain as well as the intermediate “3/4” mutant strains (p181/2-
p272/2 and p182/2-p271/2) have been previously described (11). All of the
p18-p21 and p18-p27 genotypes (wild type, p182/2, p212/2, p272/2, p182/2-
p212/2, and p182/2-p272/2) are on a mixed C57BL/6-129 genetic background.
For each genotype, intercrosses have been carried out to F9 or F10 generations
without any alteration of the observed phenotypes resulting from genetic back-
ground effects. All genotypes were confirmed by Southern blot analysis (6, 11,
19).
Anatomic and histologic analysis. Many animals were sacrificed and subjected
to complete necropsy at the first indication of morbidity (weight loss, dehydra-
tion, ataxia, or failure to thrive). Other animals (primarily wild-type or single null
animals) were sacrificed as age-matched controls. Several animals were sacrificed
between 12 and 17 months of age to analyze age-related tumor progression. Body
and organ weights were measured for every animal during necropsy. For histo-
logical analysis, tissues were fixed and processed as previously described (11).
Testes were fixed in Bouins’ solution.
Antibodies and immunochemistry. Antisera for p18, p21, p27, CDK2, CDK4,
and CDK6 and procedures for immunoprecipitations, immunoblotting, and ki-
nase assays have been previously described (11, 12, 16, 28, 38). Protein lysate
concentrations were determined by the Bradford assay and equalized for each
experiment. All Western analysis and kinase assays were performed at least twice
using independent sets of 3-month-old tissue lysates. Equal loading of lysates was
further verified by tubulin (Neomarkers, Freemont, Calif.) Western blot analysis.
Procedures for calcitonin (Dako Corporation, Carpinteria, Calif.) immunohisto-
chemistry were carried out according to the manufacturer’s suggested protocol.
Leydig cells were selectively immunostained with a monoclonal antibody, LC-
6H6 (15), which recognizes an antigen on the surface of Leydig cells, or with an
antibody against estrogen sulfotransferase (34), a Leydig cell cytosolic enzyme.
Immunostaining was visualized using the avidin-biotin-immunoperoxidase
method with diaminobenzidine as the substrate (Vectastain ABC; Vector Lab-
oratories, Burlingame, Calif.). Calcitonin and Leydig-specific immunostaining
was performed on tissue sections from several animals of all genotypes.
Kinase assays. Kinase assays have been previously described (11). Briefly, cell
lysate was prepared in ice-cold NP-40 lysis buffer from different tissues with
different genotypes and precipitated with a specific antibody for 2 h at 4°C with
rotation. Five micrograms of affinity-purified anti-mouse CDK4 antibody or 1 ml
of crude anti-CDK2 serum was used to immunoprecipitate 2 mg of cell lysate.
Protein A-agarose beads were added and incubated for 1 h with rotation at 4°C
to precipitate immunoglobulin. The beads were washed twice with NP-40 lysis
buffer and once in kinase assay buffer. The washed beads were resuspended in 25
ml of kinase assay buffer containing 5 mCi of [g-32P]ATP and 2 mg of GST-
pRbC137 substrate (a fusion protein of glutathione-S-transferase [GST] and the
C-terminal 137 amino acids of pRb) for CDK4 or 4 mg of histone H1 substrate
(Boehringer Mannheim) for CDK2 kinase assays. The reaction mix was incu-
bated at 30°C for 30 min, and the reaction was terminated by adding 20 ml of 23
loading dye (100 mM Tris-HCl [pH 6.8], 4% sodium dodecyl sulfate [SDS], 20%
glycerol, 0.2% bromophenol blue, 0.2 M dithiothreitol). Ten microliters of CDK2
or CDK4 reaction samples was resolved by SDS–15% polyacrylamide gel elec-
trophoresis (PAGE). To verify equal loading, the gel was stained with Coomassie
blue to visualize immunoglobulin and substrate proteins before it was dried and
exposed to X-ray film. Following exposure to X-ray film, the dried gels were
exposed to phosphorimaging plates. 32P incorporation was quantitated on a
PhosphorImager.
RESULTS
Generation of p18-p27 and p18-p21 double null mice. We
previously found that the progression of pituitary tumors was
greatly accelerated by the simultaneous loss of both p18 and
p27 genes and that double null mice invariably died by 3
months of age (11). To determine whether p18 and p27 may
also function in suppressing tumor growth in other tissues, we
carried out a more detailed histological analysis in the p18-p27
double null mice (n 5 33), especially in tissues where loss of
either p18 or p27 had previously been shown to cause detect-
able abnormal growth. To determine the specificity of func-
tional collaboration between different CDK inhibitor genes, we
also generated double mutant mice lacking both p18 and p21
genes and examined both the incidence and spectrum of tumor
development (n 5 18). Because the accelerated mortality of
p18-p27 double null mice might potentially exclude the detec-
tion of later-developing tumors, we also generated mice retain-
ing one allele of either p18 or p27 (p182/2-p271/2 or p181/2-
p272/2; hereafter referred to as 3/4 mutant mice). The 3/4
mutant animals have an extended life span (average, 9 months)
beyond that of double null mice, thereby allowing examination
for later-developing tumor growth. The p18-p21 double null
mice can live beyond 14 months without detectable increase in
mortality, and thus no 3/4 mutant p18-p21 mice were analyzed.
p18-p27 mutant mice were generated by crossing p182/2
mice with mice disrupted in the cyclin-CDK inhibition domain
of p27 (11, 19). Mice lacking p18 and p21 genes were gener-
ated by crossing p182/2 mice with mice deleted for p21 exon 2,
which removes 90% of the p21 coding sequence (6). Various
genotypes were verified by Southern blot analysis (Fig. 1) and
PCR (data not shown). One of the characteristic phenotypes of
both p18- and p27-deficient mice is the development of gigan-
tism and widespread organomegaly (10, 11, 19, 23). Many of
these organs (e.g., adrenal, thyroid, and testis) from p18-p27
double mutant mice displayed an even greater disproportion-
ate organomegaly (data not shown). Like the mating between
p181/2 and p271/2 mice (11), mating between p181/2 and
p211/2 mice produced all genotypes at the anticipated Men-
delian ratios, indicating that embryos with partial or complete
loss of p18 and p21 functions are viable (data not shown).
Thirty p182/2-p212/2 mice monitored between 5 and 14
FIG. 1. Genotypic analysis of CDK inhibitor genes. Southern blot analysis of p18, p21, and p27 loci. Genomic DNA from the indicated genotypes was digested with
EcoRV (p18), BglII (p21), or EcoRI (p27) and hybridized with the indicated DNA probes. The wild-type (WT) and targeted null (Mut.) alleles are indicated.
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months of age appeared developmentally normal and did not
exhibit any apparent enhancement of the p182/2 gigantism
and organomegaly phenotypes (data not shown). In distinct
contrast to p182/2-p272/2 mice, which invariably died at be-
tween 3 and 4 months of age, p182/2-p212/2 mice demon-
strated no decreased survival. These results suggest that p18
functionally collaborates with p27 but not with p21 in control-
ling organ size and body weight.
Different spectra of tumor development in p18-p27 and p18-
p21 double null mice. In addition to the previously described
pituitary adenoma (11), the p18-p27 mutant mice, including
both double null and 3/4 mutant animals, frequently developed
hyperplasia, adenomas, and/or carcinomas in seven other tis-
sues: the adrenal, thyroid, and parathyroid glands, testis, stom-
ach, duodenum, and pancreas (Table 1). With the exception of
pituitary adenomas, these tumors were rarely seen in either
single null strain. Invariably, p182/2-p272/2 animals died
around the age of 3 months and the 3/4 mutant animals died at
an average age of about 9 months from massive pituitary neo-
plasms. These results further confirm the functional redun-
dancy between p18 and p27 genes and revealed a much
broader function of these two CDK inhibitor genes in tumor
suppression than previously recognized.
Examination of p18-p21 double null mice (n 5 18) revealed
a different and more confined spectrum of tumor growth (Ta-
ble 2). Except for one animal, all of the p18-p21 double null
mice developed pituitary pathology (hyperplasia or adenomas)
by the age of 12 to 13 months (Table 2). At this age, about half
of the p182/2 mice showed pituitary hyperplasia and the re-
mainder had pituitary adenomas. Although only a few p21 null
TABLE 1. Spontaneous tumor formation and incidence in p18-, p27-, “3/4”- and p18/27-deficient micea












Normal 58/58 4/37 7/20 1/25 0/5 0/33
Hyperplasia 22/37d 8/20d 6/25 0/5 2/33
Adenoma 10/37e 5/20e 18/25 5/5 30/33
Carcinoma 1/37f 1/33
Adrenal
Normal 58/58 14/24 12/21 10/24 1/6 0/23
Medullary hyperplasia 8/24 4/21 10/24 2/6 2/23
Pheochromocytoma 2/24f 5/21 4/24 3/6 21/23g
Thyroid
Normal 63/63 36/42 23/24 11/24 3/4 2/16
C-cell hyperplasia 5/42f 1/24 11/24 0/4 13/16
C-cell adenoma 1/42f 2/24 1/4 1/16
Testis
Normal interstitium 27/27 1/41 12/12 2/17 4/5 0/10
Interstitial hyperplasia 39/41 9/17 1/5 10/10
Interstitial adenoma 1/41h 6/17
Parathyroid




Normal 16/17 15/15 14/14 6/9 3/3 4/5
Islet cell hyperplasia 1/17i 3/9 1/5
Stomach
Normal 63/63 39/39 19/23 20/21 3/6 5/14
Squamous hyperplasia 3/23 1/21 3/6 6/14
Squamous papilloma 1/23 3/14
Neuroendocrine hyperplasia 1/14
Intestine (duodenum)
Normal 59/59 39/39 19/24 20/23 4/4 2/17
Focal hyperplasia j 0/24 3/23 5/17
Villous adenoma j 5/24 10/17
Lungs
Normal 35/35 24/24 19/20 17/18 6/6 24/24
Histiocytic pneumoniae 1/20 1/18
Bronchioalveolar adenoma
Bronchioalveolar carcinoma
Liver, normal 35/35 24/24 21/21 17/17 6/6 24/24
a The numbers in the column heads are the total number of animals examined unless stated otherwise. Data are presented as number positive/number examined.
b These mice died by 8 to 9 months of age.
c These mice died by 3.5 months of age.
d Tumors developed on average by 2 to 4 months.
e Tumors developed on average by 7 to 11 months.
f Mice more than 12 months old.
g One tumor metastasized to a pelvic nerve.
h Mouse 16 months old.
i Mouse .22 months old.
j Focal lesions of Brunner’s gland.
k Mouse 11 months old.
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mice developed slight pituitary hyperplasia, loss of p21 func-
tion accelerated the incidence and progression of pituitary
pathology initiated by the loss of p18. It should be noted that
the loss of p18 and p21, like the loss of p18 and p27, enhanced
the pituitary tumor phenotype in this tissue. Therefore, in this
case, the accelerated pituitary tumor growth represents a func-
tional collaboration between p18 and p21 rather than distinct
tissue specificity from that of p18 and p27. Tissue specificity of
tumor suppression is more apparent when comparing the p18-
p27 double mutant mice with p18-p21 double mutant mice in
other tissues, where clear tissue differences are observed (e.g.,
thyroid or duodenum in p18-p27 mice and lung in p18-p21
mice).
Nearly all p18-p21 double null mice developed multifocal
gastric neuroendocrine cell hyperplasia. Gastric neuroendo-
crine cell hyperplasia was detected in a few p212/2 mice and
was not found in any p182/2 mice. At a lower incidence,
p18-p21 double null mice developed lung bronchioalveolar
adenoma or carcinoma. Two p18-p21 double null mice also
exhibited hepatic nodular hyperplasia. These results provide
the first genetic evidence for a tumor suppression function of
p21. In six tissues where p18-p27 double mutant mice devel-
oped frequent hyperplasia or tumors (adrenal, thyroid, testis,
parathyroid, pancreas, and duodenum), there is no evidence
that p18-p21 losses of function collaborate in tumor develop-
ment (Table 2). Conversely, p18 and p27 do not seem to
collaborate significantly in the formation of gastric neuroen-
docrine cell hyperplasia, lung tumors, or liver hyperplasia. The
distinct tumor spectra of p18-p27 and p18-p21 double null
mice indicate that functional collaboration between different
CDK inhibitors suppresses tumor growth with different tissue
specificities.
p18-p27 double mutant mice develop multiple types of en-
docrine tumors. Notably, five of the seven tumors that occur in
p18-p27 double mutant mice (pituitary adenoma, adrenal
pheochromocytoma, thyroid C-cell adenoma, parathyroid ad-
enoma, and testis Leydig cell adenoma), as well as the pancre-
atic islet cell hyperplasia, all involve endocrine tissues (Table 1
and Fig. 2). This affected tissue spectrum overlaps that seen in
patients with type I (MEN1, pituitary, pancreatic, and para-
thyroid tumors) or type II (MEN2, thyroid C-cell carcinomas,
pheochromocytomas, and parathyroid tumors) MEN syn-
dromes. One characteristic feature of MEN syndromes is the
concurrent development of multiple endocrine tumors in the
same patient. All of the p182/2-p272/2 and most of the 3/4
mutant animals developed multiple endocrine tumors. Most
double null animals possessed three or four tumors and had
additional hyperplastic tissues. In one p182/2-p272/2 animal,
five simultaneous tumors were detected. The most frequently
occurring hyperplastic tissues and/or tumors in p182/2-p272/2
mice were the pituitary adenoma and carcinoma (31 of 33,
94%), adrenal medullary hyperplasia and pheochromocytoma
(23 of 23, 100%), thyroid C-cell hyperplasia and adenoma (14
of 16, 88%), and testis interstitial cell hyperplasia (10 of 10
males, 100%), all four developing with near or complete pen-
etrance (Table 1). Endocrine lesions found at a lower inci-
dence were parathyroid hyperplasia and adenomas (3 of 8,
38%, p182/2-p271/2 only) and pancreatic islet cell hyperplasia
(3 of 9 [33%] in p182/2-p271/2 and 1 of 5 [20%] in double null
mice). While the p18-p27 mouse tumors may not exactly mimic
those seen in MEN patients (e.g., adenomas in mice instead of
carcinomas in humans), the affected cell types (e.g., thyroid C
cells, adrenal medullary cells, or pancreatic islet cells) and the
spectrum of simultaneous multiple endocrine tissues are strik-
ingly similar. It remains to be determined whether the devel-
opment of mouse endocrine tumors and human MEN syn-
drome have a similar molecular mechanism.
By gross examination, adrenal glands of p182/2-p272/2 an-
imals were enlarged compared with age-matched single null or
wild-type animals (data not shown). All p182/2-p272/2 mice
developed adrenal pathology (n 5 23, Table 1). Two 3-month-
old p182/2-p272/2 mice exhibited severe medullary hyperpla-
sia, while adrenals from the remaining 23 p182/2-p272/2 mice
TABLE 2. Spontaneous tumor formation and incidence in p18-,
p21-, and p18/21-deficient mice over 1 yeara








Normal 17/17 2/18 18/21 1/17




Normal 17/17 16/16 17/22 2/18
Neuroendocrine hyperplasia 5/22 16/18
Lungs
Normal 17/17 15/15 20/21 9/17




Normal 17/17 15/15 22/22 14/16
Hepatic nodular hyperplasia 2/16
Adrenal
Normal 15/15 7/17 19/19 1/13
Medullary hyperplasia 8/17 12/13
Pheochromocytoma 2/17c
Thyroid
Normal 17/17 12/18 22/22 15/17
C-cell hyperplasia 5/18 2/17
C-cell adenoma 1/18d
Testis
Normal interstitium 5/5 5/15 10/10 1/9
Interstitial hyperplasia 14/15 8/9
Interstitial adenoma 1/15
Parathyroid
Normal 17/17 15/15 16/16 12/14
Hyperplasia 2/14
Pancreas
Normal 16/17 15/15 20/20 11/12
Islet cell hyperplasia 1/17 1/12
Intestine (duodenum), normal 17/17 15/15 18/18 15/15
a See Table 1, footnote a.
b Invasion of neurohypophysis by intermediate-lobe tumor cells.
c Bilateral.
d One metastatic tumor composed of poorly demarcated nonencapsulated
hypercellular foci with collapsed follicles separated by dense interstitial infiltrates
of lymphocytes.
e Tumor implants in alveoli distant from original tumor.
FIG. 2. p18-p27 double mutant mice developed multiple endocrine tumors. (A) Malignant pheochromocytoma in p182/2-p272/2 adrenal glands. Adrenal cross
sections of 3-month-old mice were stained with hematoxylin and eosin. (B) Thyroid C-cell phenotype. The thyroid glands were immunostained for calcitonin. C-cell
hyperplasia (CH) in p182/2-p272/2 and C-cell adenomas (A) in p182/2-p271/2 mice are shown. (C) Parathyroid phenotypes. Hematoxylin and eosin staining of
parathyroid hyperplasia (PH) and adenoma (PA) in a 7-month-old p182/2-p271/2 mouse. (D) Pancreas phenotype. Hematoxylin and eosin staining of pancreatic islet
cell hyperplasia in a 9-month-old p182/2-p271/2 mouse. Several normal (N) and three hyperplastic (ICH) islets are indicated. (E) Testis interstitial cell phenotype.
(Left) Interstitial cell adenoma in the testis of a 9-month-old p182/2-p271/2 mouse stained with hematoxylin and eosin. (Right) Interstitial cell hyperplasia in the testis
of a 9-month-old p182/2-p271/2 mouse immunostained with monoclonal antibody LC-6H6, which recognizes a Leydig cell constituent.
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contained bilateral pheochromocytomas (91%) (Fig. 2A).
These tumors were detected as early as 1 month and invaded
the adrenal cortex in some animals and, in one instance, me-
tastasized to a distal pelvic nerve (data not shown). No adrenal
pathology was detected in age-matched 3-month-old wild-type
(n 5 7), p182/2 (n 5 8), or p272/2 (n 5 9) animals (data not
shown). Although adrenal pathology was detected in some
p182/2 or p272/2 animals, the age of detection was never less
than 6 months for p272/2 mice or 12 months for p182/2 mice.
The earlier age of onset and greater incidence of adrenal
phenotypes in p18-p27 double mutants clearly demonstrate
that p18 and p27 functionally collaborate in adrenal tumori-
genesis.
The thyroid glands of p182/2-p272/2 animals appeared en-
larged compared with age-matched single null or wild-type
animals (data not shown). Thyroids from most of the 3-month-
old p182/2-p272/2 animals revealed C-cell hyperplasia (13 of
16, 81%) (Fig. 2B, right). In addition, three 3/4 mutant mice (3
of 28, 11%) and one p182/2-p272/2 mouse (1 of 16, 6%)
developed thyroid C-cell adenomas (Fig. 2B, left). The C-cell
origin of these lesions was verified by immunohistochemistry
using an antibody to calcitonin, a hormone produced in thyroid
C cells (Fig. 2B). Thyroid follicular hyperplasia was occasion-
ally seen in p182/2-p271/2 mice (data not shown). Thyroid
glands of seven age-matched 3-month-old wild-type, eight
p182/2, and nine p272/2 animals were histologically normal
(data not shown). The p182/2 and p272/2 mice that developed
thyroid pathology were all over 12 months (p182/2) or 6
months (p272/2) of age.
Parathyroid hyperplasia and/or adenomas were detected in
38% (3 of 8) of the p182/2-p271/2 mice, a lower incidence
than seen in the other endocrine tissues (Table 1, Fig. 2C). The
average age at detection was 6.8 months. The absence of this
phenotype in p182/2-p272/2 mice (0 of 6) may reflect the
premature mortality (3 months) of this genotype, while the
longer-living p182/2-p271/2 mice (approximately 9 months)
survive long enough to develop this phenotype. In addition,
33% of the p182/2-p271/2 (3 of 9) and 20% of the p182/2-
p272/2 (1 of 5) mice displayed pancreatic islet cell hyperplasia
(Fig. 2D). The age at onset of islet cell hyperplasia was 8.9
months for p182/2-p271/2 mice and 2.9 months for p182/2-
p272/2 mice. The lower incidence of islet cell hyperplasia in
p182/2-p272/2 mice again may reflect premature mortality
and the time required to develop pancreatic islet cell hyper-
plasia. With the exception of one 22-month-old wild-type
mouse, the pancreatic phenotype was not detected in any wild-
type (16 of 17), p182/2 (0 of 15), p272/2 (0 of 14), or p181/2-
p272/2 (0 of 3) mice. While one wild-type and one p182/2-
p272/2 each developed pancreatic islet cell hyperplasia, the
increased rate of incidence (6% versus 20%, respectively) and
the early age at onset (22 months versus 3 months, respec-
tively) in the double mutant genotype clearly validate the dou-
ble null result.
In addition to the endocrine tumors commonly seen in MEN
patients, the p18-p27 double mutant mice also developed hy-
perplasia and tumor phenotypes in another endocrine organ,
the testis. Gross examination of p18-p27 double null males
revealed a marked increase in testicular size by 3 months of
age. While p182/2 and p272/2 males also have enlarged testes
(10, 11, 23), this phenotype was more pronounced in p182/2-
p272/2 males. Mean testis weights of mice (6 standard devi-
ation) between 1.5 and 3 months of age varied with genotype,
from 0.106 6 0.004 mg in wild-type to 0.134 6 0.009 mg in
p182/2, 0.139 6 0.023 mg in p272/2, and 0.206 6 0.020 mg in
p182/2-p272/2 mice. Testes from p182/2 males (40 of 41,
98%) displayed interstitial cell hyperplasia and/or adenoma
not seen in wild-type (n 5 27) or p272/2 (n 5 12) males (Table
1). All p18-p27 double null mice (10 of 10) and all but two of
the p182/2-p271/2 males (15 of 17, 88%) also developed in-
terstitial cell hyperplasia. The severity of interstitial cell hyper-
plasia was always greater in p182/2-p272/2 and p182/2-p271/2
mice than in age-matched p182/2 mice (data not shown). The
hyperplastic interstitial cells immunostained with antibodies
that recognize Leydig cell constituents (Fig. 2E, right), includ-
ing monoclonal antibody LC-6H6 (15) and an antibody to
estrogen sulfotransferase (34). Compared with p182/2 males,
the immunostaining intensity in p182/2-p272/2 and p182/2-
p271/2 mice was reduced in regions where interstitial cells
were densely packed with little cytoplasm, morphological
changes consistent with impaired pituitary function (2). Ade-
nomas were detected in the interstitial cell compartment in six
of the p182/2-p271/2 males between 6 and 9 months of age (6
of 17, 35%). This tumor was detected in only one p182/2 male
that was 16 months old (1 of 41, 2%). One p182/2-p271/2 male
had an adenoma that filled ;80% of the volume of one testis
(Fig. 2E, left), with a smaller adenoma present in the other
testis. Again, the absence of interstitial cell adenomas in p18-
p27 double null mice may result from their early mortality.
Clearly, even the absence of one p27 allele is sufficient to
accelerate the Leydig cell pathology that results from the loss
of p18 function.
Gastrointestinal tumors and hyperplasia in p18-p27 mice.
p182/2-p272/2 mutant mice developed two additional nonen-
docrine lesions: squamous cell hyperplasia and papillomas in
the forestomach, and duodenal hyperplasia and villous adeno-
mas (Table 1 and Fig. 3). The squamous cell lesions were focal
and always located near the esophageal inlet. The mouse fore-
stomach is normally lined with squamous mucosa, and the
hyperplasia observed in p182/2-p272/2 and 3/4 null animals is
not a metaplastic occurrence. The duodenal lesions only ap-
peared just distal to the pylorus in conjunction with prolifera-
tion of the Brunner’s glands. Incidences of the gastrointestinal
lesions in p182/2-p272/2 animals were 43% (6 of 14) for squa-
mous cell hyperplasia, 21% (3 of 14) for forestomach papillo-
mas, 29% (5 of 17) for duodenal hyperplasia, and 59% (10 of
17) for duodenal villous adenomas. Neither tumors nor hyper-
plasia was detected in these tissues in any wild-type (n 5 59) or
p182/2 (n 5 39) animals. The incidence of these phenotypes in
p272/2 (n 5 24) animals was significantly less than in the
p182/2-p272/2 mice.
p18-p21 double null mice develop pathology distinct from
p18-p27 mice. The p18-p21 double null mice developed differ-
ent spectra of tumors and hyperplastic tissues than p18-p27-
deficient mice. The incidence and progression of pituitary ad-
enoma were both greatly increased in p18-p21 double null
mice compared with p182/2 mice. By 1 year of age, 44% of
p182/2 mice developed pituitary hyperplasia and 44% exhib-
ited adenomas or carcinomas (Table 2). However, by this same
age, all but one of the p18-p21 double null mice developed
either pituitary hyperplasia (1 of 17, 6%) or adenomas (15 of
17, 88%), with almost all animals now developing pituitary
adenomas. Therefore, in a p182/2 background, loss of p21
function greatly enhanced the incidence of pituitary pathology
as well as the progression from hyperplasia to adenoma. As in
p18- or p27-deficient mice, the pituitary adenomas that devel-
oped in the p18-p21 mice originated from the intermediate
lobe (as determined by histological examination; data not
shown). It should be noted that pituitary tumors from 1-year-
old p182/2 or p182/2-p212/2 mice were histologically indis-
tinguishable and these mice did not seem to possess different
mortality rates (data not shown). This is in contrast to the short
3-month life span of p18-p27 double null mice.
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Of 18 p18-p21 double null mice, 89% developed multifocal
gastric neuroendocrine cell hyperplasia (Fig. 4A). In one in-
stance, nodules of neuroendocrine cells extended superficially
into the subjacent muscular layers of the stomach (Fig. 4B).
This could be evidence of local invasion or merely hyperplasia
of neuroendocrine cells in a naturally occurring mucosal diver-
ticulum. While local invasion is one of the few histologic indi-
cations of malignancy for neuroendocrine cell tumors (carci-
noids), the small size and multifocal nature of the lesion in this
mouse are more consistent with hyperplasia than carcinoid
tumor. Two of 17 p18-p21 mice had bronchioalveolar adenoma
(data not shown), and 1 of 17 had a bronchioalveolar carci-
noma (Fig. 4C). The presence of lung tumors in 3 of 17 p18-
p21 double null mice (18%) combined with the lack of detect-
able tumors in the lungs of any wild-type or single null animals
suggests that these tumors result from loss of p18-p21 func-
tions rather than from normal aging processes. Two p18-p21
double null mice developed hepatic nodular hyperplasia (2 of
16; data not shown), a finding that is not uncommon in older
mice of this genetic background (C57BL/6). We therefore can-
not dismiss the possibility that this may be an incidental aging
lesion and not entirely due to the p18-p21 mutations. Except
for pituitary adenomas in p182/2 mice, the tumor phenotypes
seen in p18-p21 double null mice were rarely detected in wild-
type or either single p18- or p21-null mice. In the six tissues
where p18-p27 double mutant mice developed hyperplasia
and/or tumors (adrenal, thyroid, testis, parathyroid, pancreas,
and duodenum), there is no evidence that p18-p21 loss of
function collaborates in tumor development (Table 2). Also,
there is no indication that p18 and p27 significantly collaborate
in the formation of gastric neuroendocrine cell hyperplasia,
lung tumors, or liver pathology. The distinct spectra of tumors
that form in p18-p27 or p18-p21 double mice indicate that
functional collaboration between different CDK inhibitors sup-
presses tumor growth with different tissue specificities.
Gene dosage-dependent tumor suppression in p18-p27 mice.
Comparison of mice with five different genotypes—the p182/2
and p272/2 single nulls, the two 3/4 mutants, and the p182/2-
p272/2 double null—revealed evidence for gene dosage-de-
pendent tumor suppression by p18 and p27. In many tissues,
both 3/4 mutant genotypes exhibited an intermediate pheno-
type of tumor growth, more aggressive than in either single null
animal and in most cases less severe than in the double null
mice. This was manifested in both the incidence of tumor
formation and the rate of tumor growth. First, the incidence of
tumor formation in many tissues of 3/4 null animals was de-
creased compared to double null mice but was higher com-
pared to either single null mouse strain (Table 1). For example,
pheochromocytomas occurred in 95% of p182/2-p272/2 mice
but only in 16% of the p182/2-p271/2 mice and 60% of the
p181/2-p272/2 mice despite the longer life span of 3/4 mutant
animals. Forestomach hyperplasia and adenomas were de-
tected in 62% of the double null mice, with hyperplasia de-
tected in only 5% of the p182/2-p271/2 mice and 40% of the
p181/2-p272/2 mice. Duodenal hyperplasia and adenomas
were detected in 88% of the double null mice, with hyperplasia
FIG. 3. Nonendocrine tumors in p18-p27 double mutant mice. (A) Gross appearance of stomach squamous cell papillomas (SP) and duodenal villous adeno-
mas (VA) in 3-month-old p182/2-p272/2 mouse. Bar, 5 mm. (B) Hematoxylin and eosin staining of stomach squamous cell papillomas (SP) and duodenal villous
adenomas (VA) in 3-month-old p182/2-p272/2 mouse. (C) Stomach squamous cell papilloma from panel B. (D) Duodenal villous adenoma from panel B.
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only detected in 13% of the p182/2-p271/2 mice. Gastrointes-
tinal tumors were not seen in 3/4 mutant animals (Table 1).
Other than pituitary adenomas and with the previously noted
infrequent exceptions, tumors either did not develop or were
rarely seen in wild-type or either single null genotypes (Table
1). In some tissues, the 3/4 null mice developed tumors that
were not detected in the double null mice. As previously men-
tioned, we interpret this as a result of the early mortality of the
double null animals. Because the 3/4 null mice live longer (9
months) than the double null mice (3 months), perhaps they
have sufficient time for further initiation and/or progression of
tumor formation. Second, the rate of tumor growth in some
tissues was slower in 3/4 mutant animals than in p182/2-
p272/2 mice, but was accelerated compared with either single
null mouse strain. The average age at pituitary tumor forma-
tion was 2.7 months in p182/2-p272/2 mice and 7.4 months in
3/4 mutant mice. Accordingly, the average life span increased
from 3 months in the double null mice to an average of 9
months in both types of 3/4 mice. In comparison, p182/2 mice
(9 of 31) developed pituitary tumors at an average age of 11
months, while p272/2 mice (4 of 16) developed this tumor at
an average age of 7.6 months, and both single null genotypes
routinely live well beyond 1 year. Similarly, the pheochromo-
cytoma developed by 2.6 months in p182/2-p272/2 mice and
7.3 months in 3/4 mutant mice.
Conceivably, enhancement of neoplastic transformation in
3/4 animals compared with single null mice could be caused by
an increased incidence of loss of heterozygosity that removes
the remaining wild-type allele. Three lines of evidence argue
against this possibility. First, mice heterozygous for p27 display
intermediate phenotypes in both body size and organ weights
without the loss of heterozygosity (10, 19, 23). Second, both the
p18 and p27 genes appear to be quite stable in the genome and
are rarely mutated or deleted. Third, intermediate phenotypes
were seen in both types of 3/4 genotypes and in many different
organs (Table 1). Consistent with the notion that functional
loss of the remaining wild-type allele is not the primary cause
for the augmented phenotypes seen in the 3/4 mice, we have
found no evidence for the loss of the remaining p27 allele in
multiple samples from three different types of tumors (pitu-
itary, adrenal, and thyroid) derived from p182/2-p271/2 mice
by Southern blot analysis (data not shown).
Tissue expression of CDK inhibitors. To confirm that p18,
p21, and p27 are normally expressed in the organs where pa-
thology developed in the mutant mice, we examined various
wild-type tissues by Western blot analysis for expression of p18,
p21, and p27 proteins as well as their two common targets,
CDK4 and CDK6 (Fig. 5). CDK4 and CDK6 were expressed in
all of the tissues examined. Expression of p18 was highest in
the intestines, kidney, liver, pituitary, skeletal muscle, stomach,
testes, and thyroid, although expression was detectable in all of
the tissues examined. p21 was expressed in the adrenal, intes-
tines, lung, pituitary, spleen, stomach, testes, thymus, and thy-
roid, with low expression detected in the heart and liver. p27
was expressed in all of the tissues examined, with highest ex-
pression in the adrenal gland, heart, pituitary, and skeletal
muscle. Importantly, expression of the CDK inhibitors was
consistent with the tissues where p18, p21, or p27 loss of
function caused the development of hyperplastic or tumori-
genic phenotypes. For example, p18-p21 double null mice de-
velop pituitary, gastric neuroendocrine cell, and lung tumors.
Both proteins are expressed in the pituitary, stomach, and lung.
Mice lacking both p18 and p27 exhibit tumor growth in the
adrenal, intestines, pituitary, stomach, testes, and thyroid (in-
cluding parathyroid), all tissues where p18 and p27 are readily
detectable. It should be pointed out that in some tissues, the
expression of these genes is clearly detected (e.g., p21 in ad-
renal and p27 in lung), yet loss of CDK inhibitor function does
not result in obvious tumor phenotypes. This suggests that p18,
p21, or p27 is not a rate-limiting factor for tumor formation in
any tissue where it is expressed.
FIG. 4. Tumor phenotypes in p18-p21 double null mice. (A) Hematoxylin
and eosin staining of multifocal gastric neuroendocrine cell hyperplasia in 12-
month-old p182/2-p212/2 mouse. (B) Hematoxylin and eosin staining of gastric
neuroendocrine cell hyperplasia in a 12-month-old p182/2-p212/2 mouse show-
ing extension of neuroendocrine cells into the muscular layer of the stomach. (C)
Hematoxylin and eosin staining of lung bronchioalveolar carcinoma in 12-month-
old p182/2-p212/2 mouse.
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Simultaneous loss of p18 and p27 increases G1 CDK kinase
activity. To provide a plausible molecular mechanism for the
development of the tumorigenic phenotype in these CDK in-
hibitor-deficient mice, we compared the kinase activity of two
G1 CDKs, CDK2 and CDK4, in mice of various genotypes
using either histone H1 (for CDK2) or GST-pRb (for CDK4)
as substrates. We chose four tissues, adrenal gland, testis, lung,
and skeletal muscle, from 3-month-old animals for this analy-
sis. At this age, hyperplastic or tumor phenotypes were consis-
tently detected in p182/2-p272/2 adrenal gland and testis, but
not in lung and skeletal muscle tissue or in mice of several
other genotypes (Tables 1 and 2). Such analysis would poten-
tially allow us to determine whether any change in kinase
activity precedes or follows cell transformation.
Compared with wild-type adrenal tissue, H1 kinase activity
of CDK2 remained essentially unchanged in p212/2 and
p182/2 lysate, increased about 2.4-fold in p272/2 lysate (vary-
ing between 1.5- and 3-fold in different experiments), 1.7-
fold in p182/2-p212/2 lysate, and 6-fold in p182/2-p272/2
lysate (Fig. 6A). Rb kinase activity of CDK4 increased in all
five mutant adrenal tissues: 2-fold in p182/2 lysate, 4-fold
in p212/2 lysate, 6-fold in p182/2-p212/2 lysate, 6-fold in
p272/2 lysate, and 12-fold in p182/2-p272/2 lysate. The testis
CDK2 kinase activity increased two- to fourfold in p182/2
lysate, four- to sixfold in p272/2 lysate, and synergistically
increased about eightfold in p182/2-p272/2 testis lysate (Fig.
6B). Loss of p21 had little effect on testis CDK2 kinase activity
as seen in either p212/2 or p212/2-p182/2 lysate. The testis Rb
kinase activity of CDK4 increased two- to threefold in p182/2
lysates, twofold in p212/2 lysates, four- to sixfold in p272/2
lysates, fourfold in p182/2-p212/2 lysates, and six- to sevenfold
in p182/2-p272/2 lysates. These results suggest that associated
with the development of hyperplastic growth in both the adre-
nal gland and testis, the activity of both CDK2 and CDK4
kinase was increased by the loss of p18 or p27, and the simul-
taneous loss of both genes synergistically stimulated the activ-
ity of both CDKs.
To determine whether the increase in CDK activity is con-
sequent to the development of tumor pathology, we deter-
mined both CDK2 and CDK4 kinase activity in two additional
tissues, the lung and skeletal muscle, that possessed no observ-
able tumor phenotypes at 3 months of age. The lung CDK2
activity was increased approximately twofold in p212/2,
p272/2, p182/2-p212/2, and p182/2-p272/2 genotypes with no
apparent synergistic effects. Lung CDK4 activity was un-
changed in p182/2 or p212/2 lysates and was increased ap-
proximately threefold in p272/2, p182/2-p212/2 and p182/2-
p272/2 genotypes. In the skeletal muscle, CDK2 activity was
increased approximately twofold in p182/2 and p212/2 lysates
and approximately four to sixfold in p272/2, p182/2-p212/2,
and p182/2-p272/2 lysates. The Rb kinase activity of CDK4
was increased approximately 2-fold in p182/2 or p212/2 ly-
sates, 7- to 8-fold in p272/2 or p182/2-p212/2 lysates, and
12-fold in p182/2-p272/2 lysate.
These results provide a plausible biochemical basis—in-
crease in G1 CDK2 and CDK4 kinase activity—for the hyper-
plastic and tumor growth observed in the absence of p18, p21,
and p27. Increase in CDK2 and CDK4 kinase activity is not
dependent on and most likely precedes the development of
tumor phenotypes. While an altered proportion of cell types
resulting from hyperplastic growth and/or tumorigenesis could
potentially contribute to the change in kinase activity in double
null tissues, this would not explain the increase in kinase ac-
tivity in single null tissues where the hyperplastic phenotypes
were not as pronounced or were absent (e.g., skeletal muscle
and lung). We therefore interpret the increased kinase activity
in the single and double null tissues to be a direct effect of the
disruption of p18, p21, and/or p27. In many cases, simulta-
neous loss of two CDK inhibitor genes synergistically increased
CDK activity. This is consistent with accelerated tumorigenesis
in double mutant mice and suggests that the level of CDK
kinase activity is a rate-limiting factor for the tumor growth.
These results also indicate that an increase in G1 CDK activity
alone is not sufficient to initiate tumor growth in some tissues
(e.g., lung and skeletal muscle) and additional genetic changes
are required. Finally, an increase in CDK4 kinase activity in all
four p21- and p27-deficient tissues, adrenal, skeletal, lung, and
testis, was somewhat unexpected, given the recent report that
loss of either p21 or p27 impaired the assembly of cyclin D-
CDK4 complex and decreased Rb kinase activity of CDK4 in
in vitro-cultured mouse embryo fibroblasts (5). This finding
raises the possibility that assertion of the role of p21 and p27
as positive regulators of CDK4 may be dependent on cell types
or in vivo and in vitro kinase assay conditions.
DISCUSSION
In this report, we provided the first evidence that functional
collaborations between different CDK inhibitor genes suppress
tumor growth with distinct tissue specificities. Previously, col-
laboration between different CDK inhibitors has been thought
to contribute to differentiation of eye lens fiber cells (42) and
muscle (43), but not in general tissue tumor suppression. Our
results indicate that p18, p21, and p27 can indeed function
together as tumor suppressor genes. We have found that, ex-
cept for the pituitary, there is no overlap in the tumor spectrum
between p182/2-p272/2 and p182/2-p212/2 mice. While the
loss of both p18 and p27 resulted in spontaneous development
of multiple tumors, predominantly in endocrine organs, p18-
p21 double null mice developed pituitary adenomas, gastric
neuroendocrine cell hyperplasia, and lung bronchioalveolar
tumors. Therefore, with the exception of pituitary tumors, the
cooperative tumor suppressor activities of p18-p21 and p18-
p27 function with tissue specificity. p21 functions as the major
downstream target of p53 to cause G1 cell cycle arrest in
response to DNA damage (3, 6, 8), predicting a tumor sup-
FIG. 5. Expression of CDK and CDK inhibitors in mouse tissues. Total cell
lysates were prepared from the indicated wild-type tissues. Expression patterns
of CDK4, CDK6, p27, p21, p18, and tubulin were determined by Western blot
analysis. Tubulin expression was used to demonstrate equal loading of protein
lysates.
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pression function in vivo, yet mice lacking p21 are free of
tumor growth (6). Our results provide the first genetic evi-
dence supporting a role of p21 in tumor suppression and an
explanation—functional redundancy with another CDK inhib-
itor gene—for the lack of tumor growth in p21 single mutant
mice. It will be interesting to determine the tumor incidence
and spectra of mice lacking p21 and other CDK inhibitor
genes, especially the members of the INK4 family.
Notably, five of the seven tumors in p18-p27 double mutant
mice (pituitary adenoma, adrenal pheochromocytoma, thyroid
C-cell adenoma, parathyroid adenoma, and testis interstitial
cell adenoma), as well as the pancreatic islet cell hyperplasia,
develop in endocrine tissues. This tumor spectrum overlaps in
the same cell types as seen in human patients with MEN
syndromes (the combined MEN1 and MEN2 tumor spectra).
MEN syndromes refer to a group of diseases characterized by
the concurrent development of multiple endocrine tumors and
are clinically divided into two major subtypes, MEN1 (pitu-
itary, parathyroid, and pancreatic tumors) and MEN2 (med-
ullary thyroid C-cell carcinomas, pheochromocytomas, and
parathyroid tumors), based on their unique combinations of
affected endocrine organs (4, 29). All five endocrine organs
that are affected in MEN patients exhibit neoplastic or hyper-
plastic phenotypes in the p18-p27 mutant mice. In addition,
like MEN patients, all of the p18-p27 double null animals
possessed multiple endocrine tumors (Table 1). It should be
pointed out, however, that there are distinct differences be-
tween the p18-p27 mutant mice and MEN patients, particu-
FIG. 6. Loss of CDK inhibitors increases CDK kinase activity. Cell lysates were prepared from adrenal (A), testis (B), lung (C), and skeletal (sk.) muscle (D)
obtained from 3-month-old mice of the indicated genotypes. Equal amounts of lysate were immunoprecipitated (IP) with either anti-CDK2 or anti-CDK4 antiserum
as indicated. Competing peptides were added to the immunoprecipitations to confirm antibody specificity. Immunocomplexes were assayed for kinase activity using
histone H1 (for CDK2) or GST-pRbC137 (for CDK4) as substrates. Autoradiographs of the kinase assays are shown on the left. Incorporation of 32P was quantitated,
and relative fold change in kinase activity is graphed on the right.
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larly with nonendocrine pathology. Additional MEN1 pathol-
ogy includes foregut carcinoids, facial angiofibromas, and
multiple lipomatous tumors. MEN2B patients present addi-
tional pathology, including hyperplasia of the intrinsic auto-
nomic ganglia in the wall of the intestine, disorganized growth
of peripheral nerve axons in the lips, oral mucosa, and con-
junctiva, and developmental musculoskeletal abnormalities
(e.g., pes cavus, slipped femoral epiphyses, pectus excavatum,
and bifid ribs). These abnormalities were not detected in the
p18-p27 mutant mice. Likewise, the hyperplasia and tumors of
testis Leydig cells and gastrointestinal tumors detected in the
p18-p27 mice are not found in MEN patients. The molecular
mechanism underlying potential pathological similarities be-
tween p18-p27 mutant mice and MEN patients is not clear. It
is tempting to speculate that p18 and p27 may interact func-
tionally with the MEN1 tumor suppressor gene product, me-
nin, and/or the c-RET proto-oncogene, two genes consistently
mutated in MEN1 and MEN2 patients, respectively. While
human MEN syndromes can be clinically separated into two
major subtypes based on the affected endocrine organs, a
division of phenotypes cannot be correlated with different
p18-p27 genotypes. Further genetic and biochemical analysis is
necessary to establish a regulatory role, if any exists, for either
menin or c-Ret in controlling p18 and/or p27 function.
Like p18-p27 double mutant mice, Rb heterozygous mice
developed neoplastic phenotypes in multiple endocrine tis-
sues, including the pituitary, thyroid, parathyroid, and adrenal
glands (24), providing genetic evidence that p18 and p27 genes
function to suppress tumor growth by regulating Rb’s tumor
suppression function. The p18-p27 and Rb mutant mice exhibit
a tumor spectrum completely different from that seen in mice
lacking either p53 (7, 13, 30) or its upstream regulators ATM
(1, 39) and ARF (18), which develop predominantly lympho-
mas and soft tissue sarcomas. The molecular basis for such
dramatic differences in tumor spectrum between mice lacking
genes in the Rb and p53 pathways is not yet understood but
may be related to different roles of the Rb and p53 pathways in
tumor suppression. p53 functions primarily as a checkpoint
gene to monitor genomic integrity, while the function of Rb is
to integrate mitogenic signals to determine whether a cell is to
enter S phase for another round of division or to arrest in G1.
By allowing accumulation of mutations, loss of p53 function
would significantly increase the chance of a cell to become
tumorigenic, but only if the cell is in the active division cycle. A
stable cell cycle arrest would effectively prevent tumor devel-
opment even if the genomic integrity checkpoint pathway were
impaired. Many endocrine tissues are slow growing or contain
very few dividing cells and therefore may become more sus-
ceptible to tumorigenesis by the inactivation of the Rb pathway
resulting from the loss of both p18 and p27. Mice heterozygous
for both p53 and Rb developed multiple endocrine tumors with
a spectrum similar to those observed in the p18-p27 mice, but
more aggressive in growth (14, 37). Together, these data sup-
port a greater role for the Rb pathway (including p18, p27, and
Rb) in suppressing tumor initiation and for p53 in suppressing
tumor progression.
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